Applied Molecular Transport Inc. (AMTI)

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (Nasdaq: AMTI) (“AMT”), a biopharmaceutical company, announced today the closing of its previously announced transaction pursuant to which AMT will merge with Cyclo Therapeutics in an all-stoc.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Applied Molecular Transport Inc. (NasdaqCM: AMTI) to Cyclo Therapeutics, Inc. (NasdaqCM: CYTH). Under the terms of the proposed transaction, shareholders of Applied Molecular will receive 0.174 shares of Cyclo for each share of Applied Molecular that they own. KSF is seeking to determine whether this considera.

Company Entered into Definitive Merger Agreement with Cyclo Therapeutics Cash and Cash Equivalents of $18.1 million, as of September 30, 2023 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Applied Molecular Transport Inc. (NasdaqCM: AMTI) to Cyclo Therapeutics, Inc. (NasdaqCM: CYTH). Under the terms of the proposed transaction, shareholders of Applied Molecular will receive 0.174 shares of Cyclo for each share of Applied Molecular that they own. KSF is seeking to determine whether this considera.

GAINESVILLE, Fla. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (Nasdaq: AMTI) (“AMT”), a biopharmaceutical company, announced today that the companies have entered into a definitive agreement (the Merger Agreement) pursuant t.

Currently Pursuing Strategic Alternatives, with MTS Health Partners, L.P. Advising the Company Cash and Cash Equivalents of $22.5 million, as of June 30, 2023 SOUTH SAN FRANCISCO, Calif.

Applied Molecular Transport Inc. (AMTI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here is how Applied Molecular Transport Inc. (AMTI) and Edwards Lifesciences (EW) have performed compared to their sector so far this year.

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced its participation at the following investor conferences:

TYSONS, Va.--(BUSINESS WIRE)--Zephyr AI, Inc. (“Zephyr AI”), a high-growth healthcare technology company committed to radically reshaping traditional approaches to drug discovery and precision medicine has announced additions to its Board of Directors. The announcement follows the Company’s recent successful completion of an $18.5 million seed funding round led by Lerner Group Investments LLC and M-Cor Holdings. Zephyr AI’s Board of Directors includes internationally renowned business and technology leaders with wide ranging expertise across the health care landscape. Joining the Board as members are Roger W. Ferguson, Jr., Chief Investment Officer of Red Cell Partners, former President and CEO of TIAA, and former Vice Chairman of the Board of Governors of the United States Federal Reserve System and David L. Morgan II, President and Chief Executive Officer of Zephyr AI. In addition, representatives of the investors in the Company’s recent financing round with Board observation rights are Dr. Allen Y. Chao, founder and former Chief Executive Officer of Watson Pharmaceuticals, Michael L. Cohen, Vice President of Investments at Lerner Enterprises, and Josh Lobel, CEO and CIO of M-Cor Holdings. Current Board Member Dr. Sol J. Barer commented, “I am thrilled to welcome the new members to the Zephyr AI Board. Grant and David have strategically assembled a world-class group of leaders to guide Zephyr through their next phase of evolution and growth. I believe the team today is uniquely positioned to transform the way the biopharmaceutical industry approaches drug discovery, development, and precision analytics.” Zephyr AI CEO David L. Morgan II said, “The leadership team at Zephyr is fortunate to have this exceptional group as partners, mentors, and advocates. Their deep and unparalleled expertise will be invaluable to us as we grow our business and pursue our mission to build tools and products to support improved delivery for providers and better outcomes for patients while lowering the total cost of care.” Dr. Ferguson and Mr. Morgan join the world class Board of Directors comprised of: Dr. Sol J. Barer, PhD is a founder and former Chairman, President, COO, and CEO of Celgene. Dr. Barer currently serves as Board Chair for Teva Pharmaceuticals (TEVA.TA), NexImmune (NEXI), and Centrexion Therapeutics. He is also lead director for ContraFect Corp. (CFRX) and a member of the Board of Directors for 3DBio Therapeutics. Dr. Barer is also the Founding Chair of the Hackensack Meridian Health Center for Discovery & Innovation and is a co-founder of Barer & Son Capital, an investment fund focused on capitalizing early-stage breakthrough biotechnology companies. Dr. Barer received his Ph.D. from Rutgers University and his B.S. in chemistry from Brooklyn College of the City University of New York. Dr. Yisroel Brumer, PhD is a co-founder and the President of Red Cell Partners and a co-founder and the founding CEO of Zephyr AI. He joined Red Cell following an extensive career of executive leadership in the Department of Defense (DoD) culminating as Acting Director of Cost Assessment and Program Evaluation (CAPE). Reporting directly to the Secretary of Defense, he led the annual program review process that built the five-year defense program totaling over $3.5 trillion. Dr. Brumer also led CAPE’s oversight of all major investment programs, emphasizing analyses of alternatives, investment strategies, and programmatic tradeoffs. He led the SecDef-directed studies on high-stakes issues known as Strategic Portfolio Reviews that drove the strategic direction of the Department for the last decade. He was a member of DoD’s most senior decision bodies, including the Nuclear Weapons Council, the Missile Defense Executive Board, and the Deputy Secretary’s Management Action Group, among many others. Yisroel holds a Ph.D. in Chemical Physics and a M.Sc. in Chemistry from Harvard University and has published several works on the physics of complex systems and the application of mathematics and computation to biology and cancer. Dr. John “Jack” W. Rowe, MD is the Julius B. Richmond Professor of Health Policy and Aging at the Columbia University Mailman School of Public Health. Previously, from 2000 until late 2006, Dr. Rowe served as Chairman and CEO of Aetna, Inc., one of the nation's leading health care and related benefits organizations. Before his tenure at Aetna, from 1998 to 2000, Dr. Rowe served as President and Chief Executive Officer of Mount Sinai NYU Health, one of the nation's largest academic health care organizations. From 1988 to 1998, prior to the Mount Sinai-NYU Health merger, Dr. Rowe was President of the Mount Sinai Hospital and the Mount Sinai School of Medicine in New York City. Before joining Mount Sinai, Dr. Rowe was a Professor of Medicine and the founding Director of the Division on Aging at the Harvard Medical School, as well as Chief of Gerontology at Boston's Beth Israel Hospital. Currently, Dr. Rowe leads the MacArthur Foundation's Network on An Aging Society. Kenneth A. Samet is the MedStar Health President and Chief Executive Officer and responsible for a $7.4 billion not-for-profit, healthcare delivery system. With more than 35 years of experience in healthcare administration, Mr. Samet provides strategic oversight and management for MedStar Health—the largest healthcare provider in Maryland and the Washington, D.C., region. Prior to becoming MedStar Health’s president and chief executive officer in January of 2008, Mr. Samet served as president and chief operating officer of MedStar Health from 2003-2008; and as the system’s first chief operating officer since MedStar Health’s inception in 1998. Mr. Samet has dedicated his career to health care. He received his master’s degree in health services administration from the University of Michigan in 1982. Mr. Samet served as president of MedStar Washington Hospital Center, one of the nation’s largest tertiary care hospitals, in the District of Columbia from 1990 to 2000. From the mid-1980s to 1990, Mr. Samet held a variety of leadership positions with the Medlantic Healthcare Group, which merged with Helix Health in 1998 to create MedStar Health. Grant Verstandig is the CEO and a Founding Partner at Red Cell Partners and an accomplished entrepreneur, investor, and philanthropist. Mr. Verstandig founded Rally Health, a consumer-centric digital health company acquired by UnitedHealth Group in one of the largest digital health exits in history, and co-founded Epirus, an AI-enabled power management company focused on directed energy defense applications. Mr. Verstandig has backed numerous technology-led companies from their earliest stages through their successful transition into the public markets, including Applied Molecular Transport (AMTI), Cortexyme (CRTX), Lucira Health (LHDX), and NexImmune (NEXI), where he serves on the Board of Directors. A respected technologist as well as practitioner, Mr. Verstandig advises several public and civic institutions, including the National Security Agency where he serves as senior advisor on advanced analytics, technology, and artificial intelligence. Additions to the Board of Directors: Dr. Roger W. Ferguson Jr, JD, PhD is the Chief Investment Officer at Red Cell Partners and the Steven A Tananbaum Distinguished Fellow for International Economics at the Council on Foreign Relations. He is the former President and Chief Executive Officer of TIAA and the former Vice Chairman of the Board of Governors of the U.S. Federal Reserve System. Previously, Dr. Ferguson was head of financial services for Swiss Re, Chairman of Swiss Re America Holding Corporation, and a member of the company’s executive committee. From 1984 to 1997, he was an Associate and Partner at McKinsey & Company. He began his career as an attorney at the New York City office of Davis Polk & Wardwell. Mr. Ferguson currently serves on the boards of Alphabet Inc. (GOOGL), Blend Labs, Inc. (BLND), Corning (GLW), International Flavors and Fragrances (IFF), as well as several private companies including Klarna, Europe’s most valuable privately-owned FinTech company, Red Cell Partners, and several non-profits including Memorial Sloan-Kettering Cancer Center and the Smithsonian Institution. Mr. Ferguson served on President Obama’s Council on Jobs and Competitiveness as well as its predecessor, the Economic Recovery Advisory Board, and he co-chaired the National Academy of Sciences’ Committee on the Long-Run Macro-Economic Effects of the Aging U.S. Population. Mr. Ferguson holds a B.A., J.D., and a Ph.D. in economics, all from Harvard University. Mr. David L. Morgan II is the President and CEO of Zephyr AI and an operating partner at Red Cell. Prior to joining Zephyr he served as a Senior Vice President for Eurofins Scientific Group running a portfolio of diagnostic, biopharma, and biotechnology companies. He remains a board member of Eurofins Transplant Genomics, Viacor BioPharma Services, and Viacor Eurofins Clinical Diagnostics. Prior to Viracor, Mr. Morgan was President and CEO of VantagePoint Holdings, Inc., a private equity-backed group of diagnostic companies that were sold to Sonic Healthcare. Mr. Morgan has held senior executive positions at Cogent Healthcare, Beacon Bay Holdings, and Laboratory Corporation of America. Mr. Morgan began his career with US LABS, Inc., where he held several management positions culminating as Vice President of Operations when the company was sold to LabCorp in 2006. Following the acquisition by LabCorp, Mr. Morgan remained with the company as both Vice President and Senior Vice President. Mr. Morgan was responsible for integrating LabCorp’s many Oncology and Anatomic Pathology companies into its Oncology Division, which later became known as Integrated Oncology. Prior to his career in healthcare, Mr. Morgan was a 10-year veteran of the United States Marine Corps and remained in the Marine Corps Reserve until retiring as Colonel in 2020. He holds a bachelor’s degree from University of Pittsburgh and a master’s degree from Central Michigan University. Investors with Board Observation Rights: Dr. Allen Y. Chao, PhD is the co-founder and former Chairman and Chief Executive Office of Watson Pharmaceuticals, known today as Actavis Generics, a subsidiary of Teva Pharmaceuticals (TEVA.TA). Currently, he is the chairman and managing partner of Newport Healthcare Advisors and a trustee of the university of California, Irvine. In his twenty-five-year career at Watson, Dr. Chao grew the firm, via internal R&D, strategic M&A, and myriad licensing and acquisitions of pharmaceutical products, companies, and technologies, into the third largest supplier of generic pharmaceuticals in the US. Dr. Chao and his family were formative in the establishment of the Chao Family Comprehensive Cancer Center and the H.H. Chao Comprehensive Digestive Disease Center at the University of California, Irvine Medical Center and The Chao Center for Industrial Pharmacy at Purdue University. Dr. Chao serves as a Board Member at Tanvex Biologics, Ansun BioPharma, Arbor Pharmaceuticals, and Mithra Biotechnology. Dr. Chao hold a B.S. degree in Pharmacy from Taipei Medical College, and M.S. in Pharmaceutics from Western Virginia University, a Ph.D in Industrial and Physical Pharmacy from Purdue University, and an honorary D.Sc degree from Purdue University in recognition of his leadership and vision for the production and marketing of pharmaceutical products. Michael L. Cohen Michael L. Cohen is Vice President of Investments at Lerner Enterprises. Prior to Lerner, Michael worked at the New York City Economic Development Corporation and Blue Atlantic Capital. Michael holds a BA from the University of Pennsylvania and an MBA from the NYU Stern School of Business. Josh Lobel is the Chief Executive Officer and Chief Investment Officer of M-Cor Holdings and a co-founder of Red Cell Partners. Mr. Lobel serves on the Board of Red Cell Partners and was an early investor in and Board member of Red 6 and SkyHarbour Group. He is the Founder and former Co-Managing Partner of Archer Capital Management, an alternative investment manager that compounded top quartile returns over a 15-year period. Prior to that, Mr. Lobel was an early investment professional at Redwood Capital Management and began his career in the M&A and private equity groups of Morgan Stanley & Co. Mr. Lobel serves on the Board of Directors at Cedars-Sinai where he is the Chairman of the Investment Committee and a member of the Executive Committee. He also sits on the Board of Directors of the CIA Officers Memorial Foundation and the Advisory Board for the Center for Global Risk and Security at RAND. Mr. Lobel holds a bachelor’s degree in Economics from the University of California, Los Angeles, and a Master of Business Administration from the Wharton School at The University of Pennsylvania. ABOUT ZEPHYR AI Zephyr AI is a high-growth healthcare technology company committed to radically reshaping traditional approaches to drug discovery and precision medicine. Through partnerships and proprietary data, Zephyr AI is curating the world’s most comprehensive healthcare dataset and marrying it with cutting-edge artificial intelligence algorithms to generate novel, translatable insights to build tools and products that support both patients and providers and fuel ongoing research. At Zephyr AI, our mission-focused team of world-class software engineers and biologists leverage big data and cutting-edge technology to derive transformational insights and build enduring partnerships that will revolutionize the treatment of cancer, diabetes, and other diseases. Visit us at zephyrai.bio and follow us on Twitter, Instagram, and LinkedIn. ABOUT RED CELL PARTNERS Red Cell Partners is an incubation firm building rapidly-scalable technology-led companies that are bringing revolutionary advancements to market in healthcare and national security. United by a shared sense of duty and deep belief in the power of innovation, Red Cell is developing powerful tools and solutions to address our Nation’s most pressing problems. Visit us at redcellpartners.com and follow us on Twitter, Instagram, and LinkedIn.

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Applied Molecular Transport Inc. (“Applied Molecular” or “the Company”) (NASDAQ: AMTI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Applied Molecular issued a press release on July 6, 2022, “announc[ing] top-line Phase 2 results from the MARKET combination trial for AMT-101 in biologic-naïve patients with moderate-to-severe UC [ulcerative colitis].” According to the Company, “the data from the MARKET trial did not demonstrate added clinical benefit in the combination arm compared to the adalimumab alone arm at week 8.” Based on this news, shares of Applied Molecular fell sharply on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com. The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Applied Molecular Transport Inc. (“Applied Molecular” or “the Company”) (NASDAQ: AMTI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Applied Molecular issued a press release on July 6, 2022, “announc[ing] top-line Phase 2 results from the MARKET combination trial for AMT-101 in biologic-naïve patients with moderate-to-severe UC [ulcerative colitis].” According to the Company, “the data from the MARKET trial did not demonstrate added clinical benefit in the combination arm compared to the adalimumab alone arm at week 8.” Based on this news, shares of Applied Molecular fell sharply on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com. The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Live Conference Call and Webcast on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT) Live Conference Call and Webcast on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT)

PALO ALTO, Calif.--(BUSINESS WIRE)--VMware Inc. (NYSE: VMW), a leading innovator in enterprise software, today unveiled innovations to its anywhere workspace platform, VMware Workspace ONE, that will make it easier for IT teams to manage and better secure all employee devices. New capabilities include: “As the frequency and sophistication of threats continue to intensify, IT teams need a way to proactively detect threats across the entire device population and respond quickly. That is a tall order for taxed IT and Sec-Ops teams,” said Shankar Iyer, senior vice president and general manager, End-User Computing, VMware. “VMware Workspace ONE is ideally suited for the new security realities of enabling a hybrid workforce. Leveraging intelligence and injecting automation in every step of the process, it simplifies IT operations, improves security against modern threats, and empowers the best employee experience across any device, anywhere.” Best In Class Security for Mobile Devices Today’s mobile threat landscape is diverse, and mobile workstyles call for specialized protection from phishing and application, device, and rogue network originated threats. VMware Workspace ONE Mobile Threat Defense, a new add-on to the industry-leading Workspace ONE UEM platform, takes mobile protection to the next level. It incorporates mobile security technologies from Lookout, a leader in the space. The solution aims to address: Application-based threats including mobile malware, app vulnerabilities, and risky application behaviors and configurations. Web and content vulnerabilities exposed through phishing via email, SMS, and messaging apps. This includes malicious URLs; malicious web pages, videos, and photos; and web and content behaviors and configurations. Zero-day threats and device vulnerabilities including jailbreak and root access detection. Device risk including OS version and update adoption. Machine-in-the-middle attacks and risky behaviors such as SSL certificate stripping; forcing weaker algorithm negotiation; anomalous application network connection activity; and vulnerabilities associated with rogue Wi-Fi. Application, device, and network protection via Workspace ONE Mobile Threat Defense can be activated within Workspace ONE Intelligent Hub. For IT, this means there are no separate apps or agents to download or deploy, and vital information – including alerts and suggested resolutions – is conveyed via a resource that employees use for daily work. To learn more about Workspace ONE Mobile Threat Defense, read this blog. Simplifying Windows OS Update Management As employees embrace hybrid workstyles, traditional network-based solutions are inadequate for securing PCs against vulnerabilities. Workspace ONE combines cloud-native Windows 10 and Windows 11 management with intelligent automation to help IT more seamlessly secure PCs alongside every other endpoint, from anywhere. VMware is today introducing new Workspace ONE capabilities that will make managing updates/patches even easier and elevate the security posture of Windows devices. Workspace ONE flexibly extends to multiple content sources and unifies policy, deployment and lifecycle management of the OS from the cloud. Flexibility is an inherent feature of the new Workspace ONE Updates Lifecycle, where critical updates can be automated via approval groups, while admins retain control to hand test patches more likely to create issues. Further enhancements include ability for IT admins to: Patch OS versions, apps and drivers together, anytime, no matter if the device is on or off the company network Use analytics to determine if there are compatibility issues prior to pushing an update Define when updates are installed enabling timely rollout with least disruption to user experience Pause or roll back patches that are creating issues Create smart distribution rings that scale out based on desired SLAs Automate advanced tasks such as uninstalls, reboots, and necessary clean up tasks Communicate and delegate appropriate actions to Sec-Ops team via granular roles-based access controls Track progress via greatly improved logging, visualization, and custom dashboards To learn more about these new update management capabilities, read this blog. IT Teams Enable Secure Anywhere Work with Workspace ONE Accent Micro Technologies (AMTI) is a technology solutions and systems provider in the Philippines. Josefino "Bong" M. Paloma, executive vice president, Technology, Sales and Marketing, said, “We like Workspace ONE and Carbon Black Cloud for the simplicity and flexibility they offer. They automate many of the manual processes we used to have in provisioning our users, whether it’s installing software or enforcing security policies within the network as well as beyond the perimeter of our network.” Read the full case study. swisspro is a provider of electrical installation, information and communications technology (ICT), and automation services. Reto Marti, head of internal IT, said, “Under the old system, it took at least four hours to get a PC ready. But thanks to VMware, we have cut that to about 30 minutes, which makes life so much easier for the IT team.” Read the full case study. Zoom provides a communications platform where people can connect, share ideas, make plans, and more. Aparna Bawa, Chief Operating Officer, said, “It was critical for our security posture to align with the prominence of this moment and the critical role Zoom played in business continuity for our customers. The collaboration with VMware delivers a more secure digital workspace and enables endpoints in our organization to be better safeguarded and compliant with IT security policies.” Additional Resources Learn more about Workspace ONE, VMware’s Anywhere Workspace platform Bookmark the VMware End-User Computing blog Follow all Workspace ONE updates on Twitter, Facebook, and LinkedIn About VMware VMware is a leading provider of multi-cloud services for all apps, enabling digital innovation with enterprise control. As a trusted foundation to accelerate innovation, VMware software gives businesses the flexibility and choice they need to build the future. Headquartered in Palo Alto, California, VMware is committed to building a better future through the company’s 2030 Agenda. For more information, please visit www.vmware.com/company. VMware, Workspace ONE, Carbon Black, and Anywhere Workspace are registered trademarks or trademarks of VMware, Inc. or its subsidiaries in the United States and other jurisdictions. This article may contain hyperlinks to non-VMware websites that are created and maintained by third parties who are solely responsible for the content on such websites.

Applied Molecular Transport Inc (NASDAQ: AMTI) will prioritize the advancement of AMT-101 into late-stage clinical development.  It is preparing for the end of Phase 2 meetings with the FDA to advance AMT-101 to Phase 3 in chronic pouchitis.

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the BofA Securities 2022 Healthcare Conference in Las Vegas on Tuesday, May 10, 2022 at 2:20 p.m. ET (11:20 a.m. PT).